Targeted Financial Services LLC Makes New Investment in AbbVie Inc. $ABBV

Targeted Financial Services LLC bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,039 shares of the company’s stock, valued at approximately $1,375,000. AbbVie accounts for 1.2% of Targeted Financial Services LLC’s holdings, making the stock its 15th largest position.

Several other institutional investors and hedge funds have also modified their holdings of ABBV. Tulsa Wealth Advisors INC acquired a new position in AbbVie in the 4th quarter worth about $5,784,000. Integrated Investment Consultants LLC lifted its holdings in shares of AbbVie by 26.3% during the 4th quarter. Integrated Investment Consultants LLC now owns 14,252 shares of the company’s stock valued at $3,257,000 after buying an additional 2,967 shares during the last quarter. Koenig Investment Advisory LLC acquired a new stake in shares of AbbVie during the 4th quarter valued at about $2,929,000. NWF Advisory Services Inc. grew its stake in shares of AbbVie by 5.3% in the 4th quarter. NWF Advisory Services Inc. now owns 13,661 shares of the company’s stock valued at $3,121,000 after buying an additional 693 shares in the last quarter. Finally, Reflection Asset Management bought a new stake in shares of AbbVie in the 4th quarter valued at approximately $461,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.1%

Shares of AbbVie stock opened at $216.63 on Friday. The stock has a market capitalization of $382.74 billion, a P/E ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. The stock has a 50 day moving average price of $212.18 and a two-hundred day moving average price of $218.76. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the firm posted $2.46 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ABBV shares. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, June 7th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Evercore set a $235.00 price target on shares of AbbVie in a research note on Friday, May 15th. Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Finally, DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.